NCT05558943

Brief Summary

AML in adults represents a group of heterogeneous diseases; the prognosis remains poor despite significant therapeutic advances in recent years. In order to optimize patient care, it is necessary to have "real life" data that exhaustively reports on the patients treated in our department. The objective of this study is:

  • To describe the AML treated within the hematology department
  • To optimize the management of patients with AML.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
750

participants targeted

Target at P75+ for all trials

Timeline
48mo left

Started Oct 2025

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress15%
Oct 2025Jun 2030

First Submitted

Initial submission to the registry

June 10, 2022

Completed
4 months until next milestone

First Posted

Study publicly available on registry

September 28, 2022

Completed
3 years until next milestone

Study Start

First participant enrolled

October 1, 2025

Completed
4.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2030

Last Updated

April 2, 2025

Status Verified

April 1, 2025

Enrollment Period

4.7 years

First QC Date

June 10, 2022

Last Update Submit

April 1, 2025

Conditions

Acute Myeloid Leukemia

Keywords

Prognosis of Acute myeloblastic leukemia

Outcome Measures

Primary Outcomes (1)

  • Overall survival

    2 years after diagnosis

Secondary Outcomes (7)

  • Overall survival

    6 months after diagnosis

  • Overall survival

    1 year after diagnosis

  • Cytological remission rate

    after the phase of induction up to 24 months

  • Incomplete cytological remission rate

    after the phase of induction up to 24 months

  • Leukemia free survival rate

    24 months

  • +2 more secondary outcomes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients treated for AML at Saint-Antoine hospital

You may qualify if:

  • Age :18 years and older
  • Patients with AML
  • Non objection to research

You may not qualify if:

  • Minor patients
  • Acute promyelocytic leukemia (AML3)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Hematology, Hospital Saint Antoine

Paris, 75012, France

Location

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

  • Alexis GENTHON, MD

    Assistance Publique - Hôpitaux de Paris

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alexis GENTHON, MD

CONTACT

01 49 28 53 44alexis.genthon@aphp.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 10, 2022

First Posted

September 28, 2022

Study Start

October 1, 2025

Primary Completion (Estimated)

June 1, 2030

Study Completion (Estimated)

June 1, 2030

Last Updated

April 2, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations

FR(1)